{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:37:40Z","timestamp":1790350660500,"version":"4.1.0"},"reference-count":18,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: To assess the value of a repeat prostate-specific antigen measurement (PSA2) before magnetic resonance imaging (MRI) in men with a raised PSA (PSA1) &lt;10 \u00b5g\/L.\nMethod: Medical records of men aged &lt; 75 years referred in 2021 for PSA1 3.0\u20139.9 \u00b5g\/L (&lt; 70 years) or 5.0\u20139.9 \u00b5g\/L (70\u201374 years) were reviewed. PSA2 was sampled before MRI within 60 days from PSA1. Odds ratios (ORs) were calculated with logistic regression. Chi-square and trend-test were used for categorical variables.\nResults: A total of 341 men were included. Median time between PSA1 and PSA2 was 28 days (interquartile range 20\u201335 days). PSA normalised in 16% (95% confidence interval [CI]: 13\u201321). Younger men were more likely to have a normal PSA2 (OR: 0.95 per year older, 95% CI: 0.92\u20130.99). Among men aged &lt; 70 years, those with PSA1 &lt; 5 \u00b5g\/L were more likely to have normalised PSA2 than those with PSA1 \u2265 5 \u00b5g\/L (21% vs. 10%, p = 0.01). A greater proportion of men with normalised PSA2 had a Prostate Imaging Data and Reporting System MRI score of 1\u20133 than men with non-normalised PSA2 (93% vs. 77%, p = 0.01).\nConclusions: A clinically significant proportion of men with a moderately raised PSA value have a normal PSA2. Younger men and men with lower PSA1 were more likely to have a normal PSA2. Few men with normalised PSA2 had suspicious MRI findings. Routine repeat PSA-testing may be motivated in men with a moderately raised PSA value to save MRI resources, particularly in younger men.<\/jats:p>","DOI":"10.2340\/sju.v59.26662","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T14:46:57Z","timestamp":1709736417000},"page":"54-57","source":"Crossref","is-referenced-by-count":1,"title":["Normalised repeat serum prostate-specific antigen: associations with age and magnetic resonance imaging results"],"prefix":"10.2340","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9707-9036","authenticated-orcid":false,"given":"Hang","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1276-8471","authenticated-orcid":false,"given":"Victoria","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-9445","authenticated-orcid":false,"given":"Ola","family":"Bratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"51174","doi-asserted-by":"crossref","unstructured":"Rosario DJ, Lane JA, Metcalfe C, et al. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. Eur Urol. 2008;53(4):777\u201384.","DOI":"10.1016\/j.eururo.2007.11.064"},{"key":"51175","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2007.11.064","DOI":"10.1016\/j.eururo.2007.11.064"},{"key":"51176","doi-asserted-by":"crossref","unstructured":"De Nunzio C, Lombardo R, Nacchia A, et al. Repeat prostatespecific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancer. BJU Int. 2018;122(1):83\u20138.","DOI":"10.1111\/bju.14197"},{"key":"51177","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.14197","DOI":"10.1111\/bju.14197"},{"key":"51178","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m T, Adolfsson J, Gr\u00f6nberg H, et al. Repeat prostate-specific antigen tests before prostate biopsy decisions. J Natl Cancer Inst. 2016;108(12):djw165.","DOI":"10.1093\/jnci\/djw165"},{"key":"51179","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jnci\/djw165","DOI":"10.1093\/jnci\/djw165"},{"key":"51180","doi-asserted-by":"crossref","unstructured":"Lavall\u00e9e LT, Binette A, Witiuk K, et al. Reducing the harm of prostate cancer screening: repeated prostate-specific antigen testing. Mayo Clin Proc. 2016;91(1):17\u201322.","DOI":"10.1016\/j.mayocp.2015.07.030"},{"key":"51181","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.07.030","DOI":"10.1016\/j.mayocp.2015.07.030"},{"key":"51182","doi-asserted-by":"crossref","unstructured":"Xie J, Jin C, Liu M, et al. MRI\/transrectal ultrasound fusion-guided targeted biopsy and transrectal ultrasound-guided systematic biopsy for diagnosis of prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:880336.","DOI":"10.3389\/fonc.2022.880336"},{"key":"51183","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2022.880336","DOI":"10.3389\/fonc.2022.880336"},{"key":"51184","doi-asserted-by":"crossref","unstructured":"Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265\u201373.","DOI":"10.1080\/21681805.2022.2094462"},{"key":"51185","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2094462","DOI":"10.1080\/21681805.2022.2094462"},{"key":"51186","doi-asserted-by":"crossref","unstructured":"Connolly D, Black A, Murray LJ, et al. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? Prostate Cancer Prostatic Dis. 2009;12(1):47\u201351.","DOI":"10.1038\/pcan.2008.37"},{"key":"51187","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/pcan.2008.37","DOI":"10.1038\/pcan.2008.37"},{"key":"51188","doi-asserted-by":"crossref","unstructured":"Arsov C, Albers P, Herkommer K, et al. A randomized trial of risk-adapted screening for prostate cancer in young men \u2013 results of the first screening round of the PROBASE trial. Int J Cancer. 2022;150(11):1861\u20139.","DOI":"10.1002\/ijc.33940"},{"key":"51189","unstructured":"https:\/\/doi"},{"key":"51190","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Kijima T, Yashi M, et al. Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels. Prostate Int. 2023;11(1):27\u201333.","DOI":"10.1016\/j.prnil.2022.08.001"},{"key":"51191","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.prnil.2022.08.001","DOI":"10.1016\/j.prnil.2022.08.001"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/26662\/45510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/26662\/45510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T14:47:08Z","timestamp":1709736428000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/26662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":18,"URL":"https:\/\/doi.org\/10.2340\/sju.v59.26662","relation":{},"ISSN":["2168-1813","2168-1805"],"issn-type":[{"value":"2168-1813","type":"electronic"},{"value":"2168-1805","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}